Cell Signaling Technology, Inc. Announces Joint Commercialization Partnership with Astellas Pharma Inc. in Cancer Personalized Medicine

Published: Feb 23, 2011

DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology, Inc. (CST) of Danvers, MA announced today a joint commercialization partnership with Astellas Pharma, Inc. (Astellas) of Tokyo, Japan focused on the delivery of personalized cancer therapeutics and diagnostics. Under this agreement, CST and Astellas have pooled their respective worldwide intellectual property estates relating to the fusion kinase, EML4-ALK, to enable the commercialization of diagnostic and therapeutic products targeting this cancer enzyme. CST will have the sole rights to exploit these joint intellectual property estates in the field of human medical diagnostics worldwide. Astellas will have the sole rights to exploit these joint intellectual property rights in the field of human therapeutics worldwide.

Back to news